Abstract: Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: HX2QGTFTSDX10SX12YLX15X16X17X18AX20 EFX23X24WLX27X28X29X30X31, wherein the definitions of X2, X10, X12, X15, X16, X17, X18, X20, X23, X24, X27, X28, X29, X30 and X31 are consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Abstract: Provided are a polypeptide derivative, modified derivative or salt thereof, and use of the polypeptide derivative, modified derivative or salt thereof, wherein the polypeptide derivative, modified derivative or salt thereof comprises a polypeptide having the sequence of following general formula I, general formula I: HX2QGTFTSDX10SX12YLX15X16X17X18AX20 EFX23X24WLX27X28X29X30X31, wherein the definitions of X2, X10, X12, X15, X16, X17, X18, X20, X23, X24, X27, X28, X29, X30 and X31 are consistent with the definitions in the claims and the description. The polypeptide derivative provided by the invention has a dual agonistic effect on GC/GLP-1 receptors, so that a synergistic effect on energy metabolism is generated, which can effectively reduce blood glucose while reducing body weight and improving the body fat level, and the efficacy is better than that of a single GLP-1 receptor agonist.

Abstract: The present invention provides a polypeptide derivative, or a modified derivative or salt thereof, and use of the polypeptide derivative, or the modified derivative or salt thereof. The polypeptide derivative, or the modified derivative or salt thereof comprises a polypeptide having the sequence of the following general formula I: general formula I: HX2QGTFTSDX10SKYLX15EX17X18AX20X21FX23AWLEX28X29X30, wherein the definitions of X2, X10, X15, X17, X18, X20, X21, X23, X28, X29, and X30 are consistent with those in the claims and description. The polypeptide derivatives of the present invention are dual agonists for GC/GLP-1 receptor, have a synergic effect on energy metabolism, can effectively reduce weight and improve a body fat level while reducing blood glucose, and have a potential application value in the field of treatment of metabolic diseases such as diabetes and obesity.